PARIS--(BUSINESS WIRE)--Keen Eye, a company that designs, develops and markets innovative image analysis solutions for research and the medical sector, announced today a 1.5 million fund raising from Seventure Partners’ Quadrivium seed fun.
Thanks to this financing, the company will develop its Keen Eye image interpretation platform for the digital pathology market, marketed as a Software-as-a-Service (SaaS) offer. It allows users to share, view and analyze all types of biological samples, using innovative image processing and artificial intelligence algorithms, from anywhere and on any device (laptop, tablet, smartphone).
According to Sylvain Berlemont, Founder and President of Keen Eye, "biomedical research is severely lacking in solutions for digital automation. Many activities carried out daily in pathology and research labs, or in contract-research organizations, are extremely time-consuming and often conducted by hand. Screening huge histological images in search of isolated tumor cells is usually similar to looking for a needle in a haystack, in a very limited time. This is particularly true for extemporaneous examinations where time is a key factor. Thanks to our interpretation platform, doctors and scientists will save a considerable amount of time for the benefit of patients and biomedical research."
According to Philippe Tramoy, Partner at the Quadrivium 1 seed fund, "the images overwhelm academic laboratories, producing a mass of information for which the existing analytical tools are obsolete. The innovative platform from Keen Eye has all the features to revolutionize the routine analysis of images."
About Keen Eye: www.keeneye.tech
About Seventure Partners: www.seventure.fr
About the seed fund Quadrivium 1: http://www.seventure.fr/en/our-institutional-funds